Toll-like receptor agonists Porphyromonas gingivalis LPS and CpG differentially regulate IL-10 competency and frequencies of mouse B10 cells

Abstract

IL-10 expressing regulatory B cells (B10) play a key role in immune system balance by limiting excessive inflammatory responses. Effects of toll-like receptor signaling and co-stimulatory molecules on B10 activity during innate and adaptive immune responses are not fully understood. Objective: This study is to determine the effects of P. gingivalis LPS and CpG on B10 cell expansion and IL-10 competency in vitro. Material and Methods: Spleen B cells were isolated from C57BL/6J mice with or without formalin-fixed P. gingivalis immunization. B cells were cultured for 48 hours under the following conditions: CD40L, CD40L+LPS, CD40L+CpG, and CD40L+LPS+CpG in the presence or absence of fixed P. gingivalis. Percentages of CD1dhiCD5+ B cells were measured by flow cytometry. IL-10 mRNA expression and secreted IL-10 were measured by real-time quantitative PCR and by ELISA respectively. Results: P. gingivalis LPS plus CD40L significantly increased CD1dhiCD5+ B cell percentages and secreted IL-10 levels in both immunized and non-immunized mice B cells in the presence or absence of P. gingivalis, compared with control group. Secreted IL-10 levels were significantly increased in CD40L+LPS treated group compared with CD40L treatment group in the absence of P. gingivalis. CpG plus CD40L significantly decreased CD1dhiCD5+ B cell percentages, but greatly elevated secreted IL-10 levels in immunized and non-immunized mice B cells in the absence of P. gingivalis, compared with CD40L treatment group. Conclusions: P. gingivalis LPS and CpG differentially enhance IL-10 secretion and expansion of mouse B10 cells during innate and adaptive immune responses.

Keywords: IL-10. Porphyromonas gingivalis LPS.
Introduction

IL-10 expressing regulatory B cells (B10) is a specific IL-10 competent regulatory B cell subset that has been recently identified in both mice and humans. B10 cell down-regulates autoimmune disease, inflammation and immune responses through IL-10 expression, playing crucial regulatory roles in innate and adaptive immunity. Though mouse B10 cells share some overlapping phenotypic markers with other multiple phenotypically defined B cell subsets, they have been found to be predominantly enriched in spleen CD1d<sup>high</sup>CD5<sup>+</sup> B cells. In mice, TLRs, which belong to pattern recognition receptors, are specialized transmembrane proteins that mediate innate immunity through detecting common structures of many microbial species such as bacterial lipopolysaccharides (LPS) or viral nucleic acids. Upon recognition of a pathogen, TLRs initiate a signaling cascade that leads to expression and release of pro-inflammatory cytokines, chemokines, and Type-I interferons. Porphyromonas gingivalis (P. gingivalis) LPS has been shown to be able to activate both TLR2 and TLR4 due to its unique structure and function. CpG responses are recognized by TLR9 agonist to stimulate the immune response.

Interaction between CD40 Ligand (CD40L) and CD40 plays an important role in the initiation and progression of cellular and humoral adaptive immunity. The activation of CD40 on B cells by CD40L is crucial for T cell-dependent B cell proliferation, differentiation, and antibody isotype switching. Recent studies demonstrated that culturing spleen B cells with LPS or CD40L for 48 h induced significantly higher frequencies of cytoplasmic IL-10 production in B cells than control. LPS stimulation of spleen B cells for 24 h induced more IL-10 than unstimulated cells. Spleen B cells with a CD1d<sup>high</sup>CD21<sup>+</sup>CD23<sup>−</sup> MZ phenotype can produce IL-10 in response to CpG stimulation in mice with lupus-like autoimmune disease. However, despite all these findings, the effects of TLR agonists along with co-stimulatory molecules, such as CD40L, on B10 activity during innate and adaptive immune responses are not clearly understood. Furthermore, there is limited information on the role of B10 cells during immune responses to oral diseases, such as periodontal disease, when encountering oral pathogens and their derivatives. In the present study, spleen B cells from P. gingivalis non-immunized and immunized mice were co-stimulated with TLR4, TLR9, and CD40 signals to investigate their effects on B10 cell expansion and IL-10 competency in vitro.

Material and Methods

P. gingivalis culture and fixation

P. gingivalis (strain ATCC 33277) were grown on anaerobic blood agar plates (NHK agar, Northeast Laboratory, Waterville, ME, U.S.A.) in an anaerobic chamber with 85% N<sub>2</sub>, 5% H<sub>2</sub>, and 10% CO<sub>2</sub>. Single colony of P. gingivalis was isolated from the plate and grown in ATCC Medium 2722. After incubation at 37°C for 4 d, bacteria number in culture medium was determined by reading optical density values using spectrophotometer and comparing them with a curve derived from a standard plate count. Bacteria were collected and fixed with 4% paraformaldehyde (PFA) for 30 min at room temperature, then washed three times with sterile phosphate-buffered saline (PBS) and resuspended in PBS at the concentration of 5×10<sup>9</sup>/mL.

Animals

C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME, U.S.A.) aging 8-10 weeks were equally and randomly divided into four groups. Group 1 and 2 were set as non-immunized mice groups in which mice were sacrificed directly for spleen B cell isolation. Group 3 and 4 were set as immunized mice groups and mice were immunized by 1×10<sup>8</sup> P. gingivalis intraperitoneal injection at day 0, then followed by 1×10<sup>7</sup> fixed P. gingivalis injection at day 7 to enhance the immunization. Mice were sacrificed for B cell isolation at day 10. All mice used in the study were maintained under pathogen-free conditions in laminar flow cabinets. Experimental protocols were approved by the Institutional Animal Care and Use Committee of the Forsyth Institute.

B cell isolation

Mice were euthanized in CO<sub>2</sub> chamber and spleens were harvested. Single splenic cells were yielded by grinded on a steel mesh and then filtered with 100 μm Cell Strainers. After red blood cells removal by Ammonium-Chloride-Potassium (ACK) lysis buffer (Life Technologies, Carlsbad, CA, USA), splenic cells were resuspended in PBS and filtered with 40 μm...
Cell Strainers. Then non-B cells were magnetically labeled using Pan B cell isolation kit (Miltenyi Biotec, Cambridge, MA, USA). Briefly, single splenic cell suspensions were incubated with biotin-conjugated monoclonal antibodies against non-B cell surface markers (CD4, CD11c, CD49b, CD90, Gr-1, and Ter119) at 4°C for 10 min followed by incubation with magnetic microbeads conjugated anti-biotin antibodies at 4°C for 15 min. Magnetically labeled cells were then depleted by passing through LD columns (Miltenyi Biotec, Cambridge, MA, USA) under the magnetic field of the QuadroMACS™ Separator (Miltenyi Biotec, Cambridge, MA, USA). Unlabeled cells that passed through LD column were collected (contained >98.5% CD19+ cells).

B cell culture

B cell number was counted by hemacytometer. Each 1×10⁶ B cells were cultured in 200 μL IMDM+GlutaMAX™ (Life Technologies, Carlsbad, CA, USA) complete medium (contains 10% FCS, 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM L-glutamine, 2.5 μg/mL Amphotericin B and 50 μM 2-ME) in 96-well plates under the following conditions: control, CD40L, CD40L+LPS, CD40L+LPS+LPS or CD40L+LPS+PE in the absence or in the presence of fixed P. gingivalis. Final concentrations of these stimulants were as follows: CD40L (eBioscience, San Diego, CA, USA, 1 μg/mL), P. gingivalis LPS (Invivogen, San Diego, CA, USA, 10 μg/mL), mouse CpG-DNA (HyClone, Plymouth Meeting, PA, USA, 10 μM), and fixed P. gingivalis (5×10⁶/1×10⁶ cells). P. gingivalis LPS was used as TLR4 agonist and mouse CpG-DNA(5'-TTCATGACGTTCCTGATGCT -3') was used as TLR9 agonist. B cells cultured without stimulation were used as control. Cells were cultured for 48 h to determine CD1dhighCD5+ B cell percentages and remaining cells were used to determine IL-10 mRNA expression levels. Culture supernatant was used for secreted IL-10 levels measurement.

CD1dhighCD5+ B cells percentages determination

B cells were washed with PBS and Fc receptors were blocked by incubating with TruStain fcX™ (BioLegend, San Diego, CA, USA) on ice for 10 min, then followed by incubation with PE anti-mouse CD1d (BioLegend, San Diego, CA, USA) and Alexa Fluor 647 anti-mouse CD5 fluorescence conjugated antibodies (BioLegend, San Diego, CA, USA) on ice for 30 min using predetermined optimal concentrations. Then, all cells were counted by flow cytometers (BD Biosciences, San Jose, CA, USA) and data were analyzed by FlowJo v10 software. For each sample, the same gate was applied to the other samples to determine their CD1dhighCD5+ B cell percentages. Since mouse B10 cells has been found to be predominantly enriched in spleen CD1dhighCD5+ B cells, CD1dhighCD5+ B cell percentage is considered as the proportional indicator of B10 cell percentage.

IL-10 mRNA expression measurement

Total mRNA of B cells was isolated by PureLink RNA Mini Kit (Life Technologies, Carlsbad, CA, USA) following the manufacturer's instructions. Isolated mRNA was then reverse transcribed to cDNA using the SuperScript™ II Reverse Transcriptase system (Invitrogen, San Diego, CA, USA) in the presence of random primers following the manufacturer's instructions. Then, real-time quantitative PCR (RT-qPCR) was carried out in a 20 μL reaction system using LightCycler 480 SYBR Green I Master kit (Roche Diagnostics, Indianapolis, IN, USA) and LightCycler 480 Instrument (Roche Diagnostics, Indianapolis, IN, USA). 2 μL cDNA template was used for each sample and measured in duplicate. 250 nM pre-designed IL-10 (Invitrogen, San Diego, CA, USA) or GAPDH primers (Sigma, St. Louis, MO, USA) were used and their sequences were as follows: IL-10, forward 5'-GACCAGCTGGACAACATACTGCTAA-3' and reverse 5'-GATAAGGCTTGGCAAACCCAAGTAA-3'; GAPDH, forward 5'-CCCCAGCAAGGACACTGAGCAA-3' and reverse 5'-GTGGGTGCAGCGAACTTTATTGATG-3'. RT-qPCR conditions were: 95°C for 10 min, followed by 45 cycles of 95°C for 10 s, 55°C for 15 s, and 72°C for 30 s. Melting curves were acquired to check the target cDNA amplification specificity. IL-10 mRNA expression level were presented as fold changes relative to GAPDH reference.

Secreted IL-10 level measurement

Secreted IL-10 levels in the cultured supernatant were measured by Mouse IL-10 ELISA MAX Standard Kit (BioLegend, San Diego, CA, USA) following the manufacturer’s manual. All samples were immediately diluted prior to measure and measured in duplicate. Absorbance values were read by Synergy HT Microplate Reader (Biotek, Winooski, VT, USA)
at 450 nm and IL-10 concentrations were calculated according to standard curve and dilution ratio.

Statistical analysis

All quantitative data were expressed as means±SD. Statistical analysis was performed using Student’s t-test for comparisons of two groups. Statistical significance was set at p<0.05.

Results

Non-immunized mice CD1d<sup>hi</sup>CD5<sup>+</sup> B cell expansion with CD40L, LPS, and CpG treatment with/without *P. gingivalis* co-stimulation

B cells separated from non-immunized mice splenocytes were cultured for 48 h under multiple conditions including CD40L, CD40L+LPS, CD40L+CpG, and CD40L+LPS+CpG (Figure 1a); *P. gingivalis*, *P. gingivalis*+CD40L, *P. gingivalis*+CD40L+LPS, *P. gingivalis*+CD40L+CpG, and *P. gingivalis*+CD40L+LPS+CpG (Figure 1b). The percentage of CD1d<sup>hi</sup>CD5<sup>+</sup> B cell was measured and quantified by flow cytometry for each group. Compared with non-treatment control group, CD40L significantly induced CD1d<sup>hi</sup>CD5<sup>+</sup> B cell expansion and CD40L+LPS had similar significant induction; however, additional CpG significantly suppressed CD40L-induced CD1d<sup>hi</sup>CD5<sup>+</sup> B cell expansion with or without LPS (Figure 1c). CD1d<sup>hi</sup>CD5<sup>+</sup> B cell population had no significant change under fixed *P. gingivalis* treatment only, comparing with non-treatment control group; and the induction by CD40L and CD40L+LPS or suppression by additional CpG were not affected by additional *P. gingivalis* treatment (Figure 1d). Taken together, with or without *P. gingivalis* treatment on non-immunized mouse splenocyte B cells, CD40L and CD40L+CpG significantly induced CD1d<sup>hi</sup>CD5<sup>+</sup> B cell expansion and CpG reduced this expansion significantly (Table 1).

Immunized mice CD1d<sup>hi</sup>CD5<sup>+</sup> B cell expansion with CD40L, LPS, and CpG treatment with/without *P. gingivalis* co-stimulation

B cells separated from immunized mice splenocytes were cultured for 48 h under the same conditions previously mentioned and measured by flow cytometry (Figures 2a, 2b). Compared with non-treatment control group, CD40L significantly induced CD1d<sup>hi</sup>CD5<sup>+</sup> B cell expansion and additional LPS slightly reduced this induction; also, additional CpG largely suppressed CD40L-induced CD1d<sup>hi</sup>CD5<sup>+</sup> B cell expansion with or without LPS (Figure 2c). For immunized mice, CD1d<sup>hi</sup>CD5<sup>+</sup> B cell population also had no significant change with fixed *P. gingivalis* treatment alone, comparing with non-treatment control group; and the induction by CD40L or suppression by additional CpG were not affected by additional *P. gingivalis* treatment. However, additional LPS inhibition effect on CD40L induction was vanished with *P. gingivalis* treatment (Figure 2d) comparing with no *P. gingivalis* treatment (Figure 2c) in immunized mice B cells (Table 2). These results indicated that B cells from *P. gingivalis* immunized mice had partial similar responses for CD40L, CD40L+LPS, and CD40L+CpG treatment with or without *P. gingivalis* co-stimulation, compared with B cells from non-immunized mice. Other than that, LPS significantly reduced the expansion of immunized CD1d<sup>hi</sup>CD5<sup>+</sup> B cell without *P. gingivalis* (Figure 2c), but had no effect on non-immunized CD1d<sup>hi</sup>CD5<sup>+</sup> B cell (Figure 1c); also, compared with *P. gingivalis* only treatment group, CD40L+*P. gingivalis* treatment had no significant induction in immunized CD1d<sup>hi</sup>CD5<sup>+</sup> B cell (Figure 2d), but induced significant expansion in non-immunized CD1d<sup>hi</sup>CD5<sup>+</sup> B cell (Figure 1d).

IL-10 mRNA levels in B cells from non-immunized and immunized mice with CD40L, LPS, and CpG treatment with/without *P. gingivalis* co-stimulation

IL-10 mRNA levels were measured and analyzed by RT-qPCR in cultured B cells separated from non-immunized mice (Figures 3a and 3b) and immunized mice (Figures 3c and 3d) with multiple treatments including CD40L, CD40L+LPS, CD40L+CpG, and CD40L+LPS+CpG (Figures 3a and 3c); *P. gingivalis*, *P. gingivalis*+CD40L, *P. gingivalis*+CD40L+LPS, *P. gingivalis*+CD40L+CpG, and *P. gingivalis*+CD40L+LPS+CpG (Figures 3b and 3d). Comparing with non-treatment control group, CD40L significantly increased IL-10 mRNA expression and additional LPS enhanced this increase in B cells from non-immunized mice (Figure 3a), but not from immunized mice (Figure 3c). However, additional CpG largely increased IL-10 mRNA expression compared with CD40L treatment with or without LPS in B cells from both types of mice (Figures 3a and 3c). *P. gingivalis* stimulation significantly increased...
Figure 1- B10 cell expansion in non-immunized mouse splenocyte B cells after CD40L, LPS, and CpG treatment with/without *P. gingivalis* co-stimulation. Splenocyte B cells were separated from non-immunized C57/BL6J mice and cultured 48 hours with CD40L (1 μg/mL), CD40L (1 μg/mL)+*P. gingivalis* LPS (10 μg/mL), CD40L (1 μg/mL)+CpG (10 μM), and CD40L (1 μg/mL)+*P. gingivalis* LPS (10 μg/mL)+CpG (10 μM) in the absence or in the presence of fixed *P. gingivalis* (5×10⁶ per 1×10⁶ cells). CD1⁹highCD5⁺ B cells were detected using flow cytometry in control and treatment groups without *P. gingivalis* (a) and with *P. gingivalis* (b) (X-axis: CD5 PE staining; Y-axis: CD1d APC staining). The percentage of CD1⁹highCD5⁺ B cells was quantified and analyzed by FlowJo software in control and treatment groups without *P. gingivalis* (c) and with *P. gingivalis* (d) (mean±SD, n=3, *p<0.05, detailed statistics information in Table 1)
IL-10 mRNA expression, and this enhancement was significantly suppressed with additional CD40L, CD40L+LPS, CD40L+CpG, and CD40L+LPS+CpG in B cells from both types of mice (Figures 3b and 3d). Taken together, CD40L+LPS and CD40L+CpG induced significant increase of IL-10 mRNA expression without \textit{P. gingivalis} treatment; however, these additional combinations suppressed the induction of IL-10 mRNA expression caused by \textit{P. gingivalis}.

Secreted IL-10 levels in B cells from non-immunized and immunized mice with CD40L, LPS, and CpG treatment with/without \textit{P. gingivalis} co-stimulation

Secreted IL-10 levels were measured and analyzed by ELISA from supernatant of cultured B cells separated from non-immunized mice (Figure 4a and 4b) and immunized mice (Figures 4c and 4d). Comparing with non-treatment control group, CD40L significantly increased IL-10 secretion in B cells from non-immunized mice only and additional LPS enhanced this increase in B cells from both type of mice (Figures 4a and 4c). Also, additional CpG largely increased IL-10 secretion compared with CD40L treatment with or without LPS in B cells from both types of mice (Figures 4a and 4c). \textit{P. gingivalis} stimulation alone significantly increased IL-10 secretion and this induction was significantly suppressed with additional CD40L+CpG, but additional CD40L and CD40L+LPS had no impacts on this induction (Figures 4b, 4d). These results suggested that CD40L+LPS and CD40L+CpG significantly increased IL-10 secretion without \textit{P. gingivalis} treatment; however, \textit{P. gingivalis} treatment significantly induced IL-10 secretion, additional Cd40L+LPS had no effect, and CD40L+CpG significantly inhibited this induction.

**Table 1** - Analysis of CD1d\textsuperscript{hi}/CD5\textsuperscript{hi} B cells percentage statistics in groups without \textit{P. gingivalis} treatment

| Fig.1c | Control | CD40L | CD40L+LPS | CD40L+CpG | CD40L+LPS+CpG |
|--------|---------|-------|-----------|-----------|--------------|
| Control | p<0.05  | p<0.05| p<0.05    | p<0.05    | p<0.05       |
| CD40L  | p<0.05  | p<0.05| p<0.05    | p<0.05    | p<0.05       |
| CD40L+LPS | p<0.05 | p<0.05| p<0.05    | p<0.05    | p<0.05       |
| CD40L+CpG | p<0.05 | p<0.05| p<0.05    | p<0.05    | p<0.05       |
| CD40L+LPS+CpG | p<0.05 | p<0.05| p<0.05    | p<0.05    | p<0.05       |

**Table 2** - Analysis of CD1d\textsuperscript{hi}/CD5\textsuperscript{hi} B cells percentage statistics in groups with \textit{P. gingivalis} treatment

| Fig.1d | Control | \textit{Pg} | \textit{Pg}+CD40L | \textit{Pg}+CD40L+LPS | \textit{Pg}+CD40L+CpG | \textit{Pg}+CD40L+LPS+CpG |
|--------|---------|-------------|------------------|----------------------|-----------------------|---------------------------|
| Control | p<0.05  | p<0.05      | p<0.05           | p<0.05               | p<0.05                | p<0.05                    |
| \textit{Pg} | p<0.05  | p<0.05      | p<0.05           | p<0.05               | p<0.05                | p<0.05                    |
| \textit{Pg}+CD40L | p<0.05 | p<0.05      | p<0.05           | p<0.05               | p<0.05                | p<0.05                    |
| \textit{Pg}+CD40L+LPS | p<0.05 | p<0.05      | p<0.05           | p<0.05               | p<0.05                | p<0.05                    |
| \textit{Pg}+CD40L+CpG | p<0.05 | p<0.05      | p<0.05           | p<0.05               | p<0.05                | p<0.05                    |

| Fig.2d | Control | \textit{Pg} | \textit{Pg}+CD40L | \textit{Pg}+CD40L+LPS | \textit{Pg}+CD40L+CpG | \textit{Pg}+CD40L+LPS+CpG |
|--------|---------|-------------|------------------|----------------------|-----------------------|---------------------------|
| Control | p<0.05  | p<0.05      | p<0.05           | p<0.05               | p<0.05                | p<0.05                    |
| \textit{Pg} | p<0.05  | p<0.05      | p<0.05           | p<0.05               | p<0.05                | p<0.05                    |
| \textit{Pg}+CD40L | p<0.05 | p<0.05      | p<0.05           | p<0.05               | p<0.05                | p<0.05                    |
| \textit{Pg}+CD40L+LPS | p<0.05 | p<0.05      | p<0.05           | p<0.05               | p<0.05                | p<0.05                    |
| \textit{Pg}+CD40L+CpG | p<0.05 | p<0.05      | p<0.05           | p<0.05               | p<0.05                | p<0.05                    |
Figure 2- B10 cell expansion in immunized mouse splenocyte B cells after CD40L, LPS, and CpG treatment with/without P. gingivalis co-stimulation. C57BL/6J mice were immunized by intraperitoneal injection of fixed P. gingivalis on day 0 (1×10^6) and day 7 (1×10^6). Splenocyte B cells were separated from immunized mice on day 10 and cultured 48 hours with CD40L (1 µg/mL), CD40L (1 µg/mL)+P. gingivalis LPS (10 µg/mL), CD40L (1 µg/mL)+CpG (10 µM), and CD40L (1 µg/mL)+P. gingivalis LPS (10 µg/mL)+CpG (10 µM) in the absence or in the presence of fixed P. gingivalis (5×10^6 per 1×10^6 cells). CD1^hi^CD5^+^ B cells were detected using flow cytometry in control and treatment groups without P. gingivalis (a) and with P. gingivalis (b) (X-axis: CD5 PE staining; Y-axis: CD1d APC staining). The percentage of CD1^hi^CD5^+^ B cells was quantified and analyzed by FlowJo software in control and treatment groups without P. gingivalis (c) and with P. gingivalis (d) (mean±SD, n=3, *p<0.05, detailed statistics information in Table 2)
Toll-like receptor agonists *Porphyromonas gingivalis* LPS and CpG differentially regulate IL-10 competency and frequencies of mouse B10 cells.

**Figure 3** - IL-10 mRNA expression in B cells from non-immunized and immunized mice with CD40L, LPS, and CpG treatment with/without *P. gingivalis* co-stimulation. Splenocyte B cells were separated and cultured 48 hours with CD40L (1 μg/mL), CD40L (1 μg/mL)+*P. gingivalis* LPS (10 μg/mL), CD40L (1 μg/mL)+CpG (10 μM), and CD40L (1 μg/mL)+*P. gingivalis* LPS (10 μg/mL)+CpG (10 μM) in the absence or in the presence of fixed *P. gingivalis* (5×10^6 per 1×10^6 cells). IL-10 expressions were determined by RT-qPCR in control and treatment groups without *P. gingivalis* (a) and with *P. gingivalis* (b) from non-immunized C57/BL6J mice, and same groups from immunized C57/BL6J mice without *P. gingivalis* (c) and with *P. gingivalis* (d) (mean±SD, n=3, *p<0.05*).
Figure 4- Secreted IL-10 levels in B cells from non-immunized and immunized mice with CD40L, LPS, and CpG treatment with/without *P. gingivalis* co-stimulation. Splenocyte B cells were separated and cultured 48 hours with CD40L (1 µg/mL), CD40L (1 µg/mL)+*P. gingivalis* LPS (10 µg/mL), CD40L (1 µg/mL)+CpG (10 µM), and CD40L (1 µg/mL)+*P. gingivalis* LPS (10 µg/mL)+CpG (10 µM) in the absence or in the presence of fixed *P. gingivalis* (5×10⁶ per 1×10⁷ cells). Medium supernatants were collected and secreted IL-10 protein levels were measured by ELISA in control and treatment groups without *P. gingivalis* (a) and with *P. gingivalis* (b) from non-immunized C57/BL6J mice, and same groups from immunized C57/BL6J mice without *P. gingivalis* (c) and with *P. gingivalis* (d) (mean±SD, n=3, *p<0.05)*
Discussion

IL-10 producing B10 cells play an essential role in immune system balance by suppressing excessive inflammatory responses. However, little is known about the effects of co-stimulation by multiple TLR agonists and CD40 activator on B10 cells under different immunological conditions. In the present study, we investigated the changes of B10 cell population and IL-10 secretion by combined treatment of Porphyromonas gingivalis LPS (TLR4 agonist), CpG (TLR9 agonist), and CD40L in the context of innate immunity (cells from non-immunized mice) and adaptive immunity (cells from immunized mice). The results showed that Porphyromonas gingivalis LPS enhanced IL-10 secretion by B10 cells in mice in vitro during innate and adaptive immune responses with increased CD1d^hi^CD5^+^ B cells; However, CpG was more effective than Porphyromonas gingivalis LPS to enhance IL-10 competency during these responses with decreased CD1d^hi^CD5^+^ B cells.

Porphyromonas gingivalis LPS is a purified product of lipopolysaccharide from Gram-negative bacteria Porphyromonas gingivalis, which is considered as the main pathogen of periodontal disease. LPS is the major component of Gram-negative bacteria that activates the innate immune system. However, Porphyromonas gingivalis LPS has a unique and heterogenous chemical structure, which is different from traditionally recognized enteric bacterium-derived LPS such as Escherichia coli LPS. Porphyromonas gingivalis LPS and Escherichia coli LPS have been shown to trigger different intracellular inflammatory signaling pathways and cytokine productions. It was suggested that the structural heterogeneity of Porphyromonas gingivalis lipid A contributes to the unusual innate host response to this LPS and its ability to interact with both TLR2 and TLR4. This may explain the difference of the induction effects on B10 population and IL-10 secretion between co-stimulating Porphyromonas gingivalis LPS plus CD40L and Escherichia coli LPS plus CD40L in non-immunized mice. In non-immunized mice without Porphyromonas gingivalis LPS treatment, additional Porphyromonas gingivalis LPS did not further increase CD1d^hi^CD5^+^ B cells percentages (Figure 1c), but significantly increased IL-10 mRNA expression (Figure 3a) and IL-10 secretion (Figure 4a) compared with CD40L only group. Moreover, in immunized mice without Porphyromonas gingivalis treatment, Porphyromonas gingivalis LPS suppressed the expansion of CD1d^hi^CD5^+^ cells induced by CD40L (Figure 2c) with an increase of IL-10 secretion (Figure 4c). These results suggest that Porphyromonas gingivalis LPS stimulation has different effects on innate and adaptive immune responses, and it may enhance the IL-10 secretion from fewer CD1d^hi^CD5^+^ B cells with higher competence or from increased B10 cells other than CD1d^hi^CD5^+^ cell subset. These differences and possible mechanisms need to be investigated in future studies. Porphyromonas gingivalis synthesizes two LPS, O-LPS and A-LPS. The structures of the O-PS and A-PS repeating units, the core oligosaccharide (OS), and the linkage of the repeating unit to the core in O-LPS and A-LPS have been extensively studied. Analysis of the detailed structure of Porphyromonas gingivalis LPS is essential for further mechanistic investigation of the antigenicity of this important periodontal pathogen.

Porphyromonas gingivalis induces periodontitis through the disruption of the host tissue homeostasis and adaptive immune response, which allows uncontrolled growth of the commensal microbial community in oral cavity. In our study, Porphyromonas gingivalis alone showed no effect on expansion or reduction of CD1d^hi^CD5^+^ cells in B cells from both immunized and non-immunized mice. However, Porphyromonas gingivalis treatment significantly increased IL-10 secretion in both immunized and non-immunized mice B cells, suggesting this induction was caused by cells other than CD1d^hi^CD5^+^ B cells or by increasing the competence of B10 cells in CD1d^hi^CD5^+^ subset. Furthermore, Porphyromonas gingivalis treatment significantly diminished the CpG-induced IL-10 production (Figures 4b and 4d) compared with groups without Porphyromonas gingivalis treatment (Figures 4a and 4c) in both innate and adaptive immune responses, suggesting that the IL-10 secretion induced by TLR9 signaling may be inhibited by components of Porphyromonas gingivalis. The mechanism of how Porphyromonas gingivalis induces IL-10 secretion and inhibits TLR9 signaling induced IL-10 secretion in splenocytes B cell needs to be further investigated.

Conclusions

With CD40L, Porphyromonas gingivalis LPS enhanced IL-10 competency of B10 cells and B10 cell expansion in the absence, but not in the presence of Porphyromonas gingivalis; however, CpG induced the stronger IL-10 competency of B10 cells but inhibited B10 expansion under the same conditions.

Acknowledgements

This study was supported by NIH NIDCR grant R21DE021837 and R56DE023807.
References

1- Andrukhov O, Eirtschweiger S, Moritz A, Bantleon HP, Rausch-Fan X. Different effects of P. gingivalis LPS and E. coli LPS on the expression of interleukin-6 in human gingival fibroblasts. Acta Odontol Scand. 2014;72(5):337-45.

2- Bainbridge BW, Coats SR, Darveau RP. Porphyromonas gingivalis lipopolysaccharide displays functionally diverse interactions with the innate host defense system. Ann Periodontol. 2002;7(1):29-37.

3- Ballini A, Cantore S, Farronato D, Cirulli N, Inchingolo P, Le Gall-David S, et al. Periodontal disease and bone pathogenesis: the crosstalk between cytokines and Porphyromonas gingivalis. J Biol Regul Homeost Agents. 2015;29(2):273-81.

4- Beutler B, Poltorak A. The sole gateway to endotoxin response: how LPS was identified as Tlr4, and its role in innate immunity. Drug Metab Dispos. 2001;29(4 Pt 2):474-8.

5- Blasco-Baque V, Garidou L, Pomié C, Escoula Q, Loubieres P, Le Gall-David S, et al. Periodontitis induced by Porphyromonas gingivalis drives periodontal microbiota dysbiosis and insulin resistance via an impaired adaptive immune response. Gut. 2016. doi:10.1136/gutjnl-2015-309897. Epub ahead of print.

6- Darveau RP, Pham TT, Lemley K, Reife RA, Bainbridge BW, Coats SR, et al. Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4. Infect Immun. 2004;72(9):5041-51.

7- Diya Z, Lili C, Shenglai L, Zhiyuan G, Jie Y. Lipopolysaccharide (LPS) of Porphyromonas gingivalis induces IL-1beta, TNF-alpha and IL-6 production by THP-1 cells in a way different from that of Escherichia coli LPS. Innate Immun. 2008;14(2):99-107.

8- Frazão JB, Errante PR, Condino-Neto A. Toll-like receptors’ pathway disturbances are associated with increased susceptibility to infections in humans. Arch Immunol Ther Exp (Warsz). 2013;61(6):427-43.

9- Gao M, Ha T, Zhang X, Wang X, Liu L, Kalbfleisch J, et al. The toll-like receptor 9 ligand, CpG oligodeoxynucleotide, attenuates cardiac dysfunction in polymeric scopolis, involving activation of both phosphoinositide 3 kinase/Akt and extracellular-signal-related kinase signaling. J Infect Dis. 2013;207(9):1471-9.

10- Gölz L, Memmert S, Rath-Denschner B, Jäger A, Appel T, Baumgarten G, et al. LPS from P. gingivalis and hypoxia increases oxidative stress in periodontal ligament fibroblasts and contributes to periodontitis. Mediators Inflamm. 2014;2014:986264.

11- Gorbacheva V, Ayasoufi K, Fan R, Baldwin WM 3rd, Valujskikh A. B cell activating factor (BAF) and a proliferation inducing ligand (APRL) mediate CD40-independent help by memory CD4 T cells. Am J Transplant. 2015;15(2):346-57.

12- Gully N, Bright R, Marino V, Marchant C, Cantley M, Haynes D, et al. Porphyromonas gingivalis peptidylarginine deiminase, a key contributor in the pathogenesis of experimental periodontal disease and experimental arthritis. PLoS One. 2014;9(6):e100838.

13- Hassan GS, Merhi Y, Mourad W. CD40 ligand: a neo-inflammatory molecule in vascular diseases. Immunobiology. 2012;217(5):521-32.

14- Jenabian MA, Patel M, Kema I, Vyboh K, Kanagaratham C, Radzioch D, et al. Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection. Clin Exp Immunol. 2014;178(1):102-11.

15- Kawabe T, Matsuhashi M, Hashimoto N, Imazumiz K, Hasegawa Y. CD40/CD40 ligand interactions in immune responses and pulmonary immunity. Nagoya J Med Sci. 2011;73(3-4):69-78.

16- Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461.

17- Lester SN, Li K. Toll-like receptors in antiviral innate immunity. J Immunol. 2014;192(6):1246-64.

18- Li J, Shen C, Liu Y, Li Y, Sun L, Jiao L, et al. Impaired function of CD5+CD19+CD1dhi B10 cells on IgE secretion in an atopic dermatitis-like mouse model. PloS One. 2015;10(8):e0132173.

19- Lin M, Lin J, Wang Y, Bonheur N, Kawai T, Wang Z, et al. Lipopolysaccharide attenuates CD40 ligand-induced regulatory B10 cell expansion and IL-10 production in mouse splenocytes. Open J Immunol. 2015;5(1):1-8.

20- Lykkene JM, Candumdo KM, Tedder TF. Regulatory B10 cell development and function. Int Immunol. 2015;27(10):471-7.

21- Miao J, Zheng L, Zhang J, Ma Z, Zhu W, Zou S. The effect of taurine on the toll-like receptors/nuclear factor kappa B (TLRs/NF-kappaB) signaling pathway in Streptococcus uberis-induced mastitis in rats. Int Immunopharmacol. 2011;11(11):1740-6.

22- Nebel D, Arvidsson J, Lillqvist J, Holm A, Nilsson BO. Differential effects of LPS from Escherichia coli and Porphyromonas gingivalis on IL-6 production in human periodontal ligament cells. Acta Odontol Scand. 2013;71(3-4):892-8.

23- Ogawa T, Suda Y, Kashiwara H, Hayashi T, Shimoyama T, Kusamoto S, et al. Immunobiological activities of chemically defined lipid A from Helicobacter pylori LPS in comparison with Porphyromonas gingivalis lipid A and Escherichia coli-type synthetic lipid A (compound 506). Vaccine. 1997;15(15):1598-605.

24- Paramonov N, Aduse-Opoku J, Hashim A, Rangarajan M, Curtis MA. Identification of the linkage between A-polysaccharide and the core in the A-polysaccharide of Porphyromonas gingivalis W50. J Bacteriol. 2015;197(10):1735-46.

25- Pellegrini A, Gallinaz N, Giordano L, Cano RC, Gea S. The role of toll-like receptors and adaptive immunity in the development of protective or pathological immune response triggered by the Trypanosoma cruzi protozoan. Future Microbiol. 2011;6(12):1521-33.

26- Singhrao SK, Harding A, Poole S, Kesavalu L, Crean S. Porphyromonas gingivalis periodontal infection and its putative links with Alzheimer’s disease. Mediators Inflamm. 2015;2015:137357.

27- Tedder TF. B10 cells: a functionally defined regulatory B cell subset. J Immunol. 2015;194(4):1395-401.

28- Xu H, Liew LN, Kuo IC, Huang CH, Goh DL, Chua KY. The modulatory effects of lipopolysaccharide-stimulated B cells on differential T-cell polarization. Immunology. 2008;125(2):218-28.

29- Yadav R, Zammit DJ, Lefrancois L, Vella AT. Effects of LPS-mediated bystander activation in the innate immune system. J Leukoc Biol. 2006;80(6):1251-61.

30- Yanaba K, Bouaziz JD, Matsuhihita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol. 2009;182(12):7459-72.